Dr. Ayman discusses the management of high-risk CLL patients with emphasis on personalised medicine and the predictors of response to alternative treatments
Dr. Ayman Al Hejazi, KSA
Edit Video Component
Dr. Ayman Al Hejazi, Assistant Professor of Haematology/Oncology, King Saud Abdulaziz University of Heath Sciences, Head and Consultant, Division of Adult Haematology and Stem Cell Transplantation, King Abdulaziz Medical City, Saudi Arabia, talks on the Definition and Management of High-Risk CLL patients with emphasis on the following
• The negative impact of TP53 aberrations, IGHV mutations on the overall survival in CLL patients
• Personalized treatment approaches in the management of CLL.
• Defining high risk CLL and its role in the careful consideration of predictors
of response to alternative treatments.
Explore more videos
Configure Image Component
Continues Therapy Versus Time Limited Therapy in High-Risk CLL Patients
Dr. Wojciech Jurczak , Poland
Configure Image Component
Panel Discussion
Dr. Ahmad Absi, KSA
Configure Image Component
Latest Updates in Management of CLL
Dr. Davide Rossi, Switzerland
Modal Window Component Section Begins
Modal Window Component Section Ends